Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (NCT01039376), a randomized phase 3 study. The primary outcome is Progression-free Survival, as Assessed by the Investigator.

2. Clinical Question

The registry describes a Phase III, randomized, open-label, multicenter trial. Its stated purpose was to determine whether maintenance treatment would prolong remission after a response to induction therapy, while also evaluating safety compared with observation. Because the study was open-label, participants and clinical teams were not masked to assignment. The primary outcome was assessed by investigators using progression definitions based on IWCLL guidance, so the interpretation concerns the registry’s investigator-assessed outcome rather than a masked central assessment.

The registry lists an enrollment of 480. The primary outcome analysis used the intent-to-treat population, defined in the record as all participants randomized. The trial status is recorded as terminated; the reason for termination is not reported in the registry record. The registry does not report whether the study’s original research question or procedures changed after enrollment began.

3. Trial Design

This was a randomized, Phase III, open-label, multicenter study of ofatumumab maintenance versus no further treatment in people with relapsed chronic lymphocytic leukemia who had responded to induction therapy. The registry lists enrollment of 480. The planned treatment period and assessment schedule were described as lasting up to 2 years after the first 1000 mg ofatumumab dose.

Participants assigned to ofatumumab received 300 mg intravenously in Week 1, followed by 1000 mg intravenously in Week 2 and then a dose of 1000 mg every 8 weeks for up to 2 years following the first 1000 mg dose. The comparator was observation. Disease status assessments to determine response or progression were scheduled approximately every 8 weeks for up to 2 years in both arms, according to IWCLL criteria. Thus, the comparator did not mean absence of follow-up; observation included scheduled assessments.

The registry describes the trial as collaborative and states that it was co-developed with the HOVON and NORDIC CLL group and conducted as a collaborative effort with GSK. Novartis Pharmaceuticals is listed as sponsor. The start date was 2010-05-06, the primary completion date was 2017-02-20, and the overall status is recorded as terminated. The reason for termination is not reported in the registry record.

The primary outcome was investigator-assessed progression-free survival, measured from randomization until progression or death from any cause, with a reported timeframe of up to 79 months. The primary analysis population was intent-to-treat. The registry reports a stratified log-rank test for the time-to-event comparison and gives the hazard ratio as the comparative measure. Details of the stratification factors, the original sample-size justification, and the trial’s full statistical analysis plan are not reported in the registry record. Randomization methods and allocation concealment details beyond the randomized allocation are also not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Eligible participants were stratified based on complete or partial remission at study entry, number of previous induction treatments (2 versus 3) and type of prior treatment (chemoimmunotherapy, only alkylating monotherapy, or other treatment). Participants were then randomized in a 1:1 ratio to receive ofatumumab or no further treatment.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Intent-to-Treat (ITT) Population: all participants who were randomized in the study.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Intent-to-treat (ITT) population included subjects who were randomized in the study. Subjects were grouped based on how they were randomized regardless of which treatment they received. This population was used for evaluation of all efficacy assessments.

6. Primary Endpoint

The registry lists the primary outcome as Progression-free Survival, as Assessed by the Investigator, measured over From randomization until progression or death (up to 79 months).

Progression-free survival is the time from randomization to disease progression or death from any cause. In this trial, progression was assessed by the investigator using IWCLL response definitions based on updated National Cancer Institute-Sponsored Working Group guidance. The registry describes progression features that include new or enlarging lymphadenopathy or organ involvement, specified increases in previously noted liver or spleen enlargement, an increase in blood lymphocytes meeting the stated criteria, transformation to a more aggressive histology, or cytopenia attributable to chronic lymphocytic leukemia.

The endpoint is useful because it combines two events relevant to the course of the disease: documented progression and death. It also uses the time until an event, rather than only recording whether an event occurred by a single fixed visit. This lets the analysis incorporate the timing of events and account for participants who have not had a recorded event by the end of their observed follow-up through censoring, although the exact censoring and missing-data procedures are not reported in the registry record.

The registry reports median progression-free survival in months for each arm and a hazard ratio from a stratified log-rank analysis. The median describes the time by which the estimated progression-free survival experience reaches the midpoint of the observed survival distribution. The hazard ratio compares event hazards over follow-up; it is not a ratio of the two medians. The registry’s endpoint definition and investigator assessment are important context when interpreting the result.

7. Results Posted in the Registry

• Ofatumumab vs Observation: hazard ratio 0.55 (95% CI 0.43–0.70), reported p < 0.001 (as reported in the registry).

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Overall Survival

• Endpoint type: Time to event: compared as a hazard ratio.
• Test: Hazard ratio as reported by the sponsor (Stratified log rank test); it was not recalculated.
• Result:
  • Ofatumumab vs Observation: hazard ratio 0.93 (95% CI 0.69–1.25), reported p = 0.605 (as reported in the registry).
• Interpretation:
  • The 95% confidence interval includes no difference (a ratio of 1), so these data do not show a statistically significant difference between Ofatumumab vs Observation and the control. The interval gives the range of effects that remain compatible with the data.

Number of Participants With Improvement in Response From Baseline

• Endpoint type: Binary: the number of participants with the event, compared as proportions.
• Test: Unadjusted two-proportion z-test, with a Wald 95% confidence interval for the risk difference.
• Result:
  • Ofatumumab: 8.3% (16/193) versus 4.2% (8/192) on control; risk difference 4.1 percentage points (95% CI -0.7 to 8.9), risk ratio 1.99 (0.87–4.54); unadjusted two-proportion z-test p = 0.094.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Ofatumumab and the control. The interval gives the range of effects that remain compatible with the data.

Time to Next Therapy

• Endpoint type: Time to event: compared as a hazard ratio.
• Test: Hazard ratio as reported by the sponsor (Stratified log rank test); it was not recalculated.
• Result:
  • Ofatumumab vs Observation: hazard ratio 0.77 (95% CI 0.62–0.96), reported p = 0.018 (as reported in the registry).
• Interpretation:
  • The 95% confidence interval excludes no difference (a ratio of 1), so the hazard of the event is statistically lower for Ofatumumab vs Observation than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

The secondary outcomes broaden the questions beyond progression-free survival. They include overall survival, improvement in response, time to next therapy, outcomes after next-line therapy, and quality-of-life measures. These outcomes capture different aspects of disease course, subsequent treatment, and participants’ reported health status; they do not all measure the same underlying effect as the primary endpoint.

Across the posted results, the overall-survival comparison is not statistically conclusive by its reported confidence interval and p-value, while time to next therapy has a reported comparison that favors ofatumumab under the sponsor’s analysis. The response-improvement outcome is posted as counts without a sponsor-reported comparative analysis. These results add context to the primary progression-free survival finding, but they do not simply confirm or negate it. Overall survival and subsequent treatment can be influenced by events and treatment decisions after progression, whereas quality-of-life measures address a different outcome domain.

Interpretation also depends on how many outcomes were tested and how they were selected. The registry lists multiple secondary outcomes, but the statistical plan for testing them, including any multiplicity adjustment or hierarchy, is not reported in the registry record. When many outcomes are examined, some nominally notable results can arise by chance. Unless a testing strategy is reported, unadjusted secondary p-values should carry less weight than a prespecified primary analysis and should be viewed as supportive or exploratory rather than as independent confirmatory evidence.

The registry does not report results for every secondary outcome in the same level of detail in the listed analyses. Differences in outcome definition, analysis population, missingness, and follow-up may also affect comparisons across endpoints; the record does not provide enough information to assess each of these issues fully. The overall pattern is therefore best read as a set of complementary but unequal-strength signals, with the primary endpoint remaining the central reported comparison.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Overall Survival
• Number of Participants With Improvement in Response From Baseline
• Time to Next Therapy
• Progression-free Survival After Next-line Therapy
• Time to Progression After Next-line Therapy
• Change From Baseline (BL) in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Chronic Lymphocytic Leukaemia 16 Item Module (EORTC QLQ-CLL 16)
• Change From Baseline in the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Score
• Change From Baseline in the Quality of Life Status as Assessed by the EuroQol-5D (EQ-5D) Scale

9. Statistical Interpretation

10. Statistical Methods Explained

The primary outcome is time-to-event data: each participant’s relevant information concerns time from randomization until progression or death, or the end of observation without a recorded event. A participant who has not experienced the event by the end of available follow-up contributes information up to that point. This is commonly called censoring. General explanation: survival methods are designed to use the observed event times while accommodating participants whose event time is not observed during the study. The registry does not report the detailed censoring rules used for this analysis.

What does the median describe?

The median progression-free survival is a point on the estimated time-to-event distribution: it is the time at which the estimated proportion remaining free of progression or death reaches the midpoint. It is not the average follow-up time, nor does it describe every participant’s experience. The registry reports medians and 95% confidence intervals for the two arms. The intervals express uncertainty around each arm’s median estimate, rather than directly testing the difference between those medians.

What does the hazard ratio describe?

The primary comparison is reported as a hazard ratio for ofatumumab versus observation. A hazard is the event rate at a particular point in follow-up among participants who have not yet experienced the event. The ratio compares those hazards between arms over the time-to-event analysis. A ratio below 1 favors a lower estimated progression-or-death hazard in the ofatumumab arm; a ratio of 1 represents equal hazards under this measure. General explanation: a hazard ratio is not a direct comparison of median times, probabilities at a particular time, or the number of events prevented.

The registry reports a stratified log-rank test for the primary comparison. General explanation: the log-rank test compares the event-time patterns between groups over follow-up, and stratification can account for prespecified grouping factors when the test is performed. The registry does not report which factors were used for stratification, so their role cannot be described more specifically.

How should the confidence interval and p-value be read?

The reported 95% confidence interval for the hazard ratio gives a range of values compatible with the data under the analysis and its assumptions. A confidence interval conveys both the estimated direction and the uncertainty around the estimate. The primary interval is entirely below 1, whereas the overall-survival interval includes 1. The p-value is a measure of how unusual data at least as incompatible with the null comparison would be if the null hypothesis and test assumptions held. It is not the probability that the null hypothesis is true, and it does not measure the size or clinical importance of an effect.

The trial is open-label and the endpoint was assessed by investigators. General explanation: when treatment assignment is known, expectations or clinical decisions can sometimes influence assessments, particularly for outcomes requiring judgment. This does not show that bias occurred in this trial, but it is relevant context for an investigator-assessed progression endpoint. The registry does not report masked central review of progression.

What is different about the response-improvement outcome?

The posted response-improvement outcome is a binary count: participants are classified according to whether improvement from baseline was recorded. The registry provides counts and analysis denominators by arm, but no sponsor-reported comparative analysis for this outcome. A risk difference expresses the difference between the observed proportions; a confidence interval around a risk difference indicates uncertainty in that contrast. Any simple re-calculation from the posted counts is unadjusted and should not be mistaken for the sponsor’s full analysis. The registry does not report an adjusted analysis for this outcome.

Why does over-dispersion matter?

General explanation: over-dispersion occurs when observed variation is greater than a statistical model expects. If a model assumes less variability than the data have, standard errors can be too small and confidence intervals can be too narrow, making evidence appear more precise than it is. Conversely, a model that allows for extra variation can better represent uncertainty in some data structures. The registry record does not identify over-dispersion as an issue or report a corresponding model for the primary time-to-event analysis, so no claim about its presence or treatment can be made for this trial.

The posted planning illustrations use a normal approximation for binary outcomes and a Schoenfeld approach for time-to-event outcomes, under the assumptions stated with those illustrations. They are calculations based on observed effects for planning purposes, not a report of the trial’s original design. The original sample-size justification and any original assumptions are not reported in the registry record.

Finally, an analysis population matters. The registry defines the primary intent-to-treat population as all participants randomized. This preserves the randomized comparison as defined in the record. The record does not provide enough detail to assess how missing endpoint data, deviations from assigned treatment, or other analysis populations were handled across all outcomes.

11. Confidence Intervals and Precision

The primary hazard ratio is 0.55, with a 95% confidence interval from 0.43 to 0.70. Because this interval does not include 1, its range is consistent with a lower progression-or-death hazard for ofatumumab than observation under the reported comparison. The interval also shows that the point estimate is not the only plausible value: the estimated relative hazard is subject to uncertainty across the range reported.

The arm-specific median estimates have their own 95% confidence intervals. For ofatumumab, the median is 34.17 months with an interval from 29.7 to 38.01 months. For observation, it is 16.89 months with an interval from 12.98 to 20.37 months. These intervals quantify uncertainty in each median estimate. They are not a confidence interval for the difference between medians, and they should not be used as a substitute for the sponsor-reported hazard-ratio analysis.

A confidence interval is not a guarantee that the true value lies inside the reported range, nor does it account for every possible source of bias or uncertainty. It is interpreted under the statistical model and analysis used. The registry reports a stratified log-rank test but does not report the stratification factors or full analysis details. The open-label design and investigator assessment also matter when considering sources of uncertainty that a confidence interval may not capture.

The overall-survival estimate is less precise for interpreting a treatment difference: the reported hazard ratio is 0.93, with a 95% confidence interval from 0.69 to 1.25. That interval includes 1 and is compatible with values on either side of equal hazards. This does not prove equivalence; it indicates that the posted estimate does not clearly distinguish the comparison from equal hazards under the reported analysis. Precision and statistical significance are related but distinct: a wide interval can leave meaningful uncertainty even when its point estimate suggests a direction.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The planning illustrations translate observed effects into sample-size or event-count requirements under stated assumptions. For binary outcomes, the figures are participants per arm. For time-to-event outcomes, the figures are total events, not participants per arm. The progression-free survival and other time-to-event planning values therefore refer to events across the comparison; the binary response-improvement illustration refers to participants per arm.

The calculations use the observed effect as a starting point and consider detecting the stated fraction of that effect. The listed assumptions are a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation; time-to-event calculations use the Schoenfeld approach. These assumptions describe the posted planning illustrations. The trial’s own original design assumptions and sample-size justification are not reported in the registry record.

The 80% power column means the planning calculation targets an 80% chance of detecting the stated effect if that effect is present and the assumptions hold. The 90% power column uses a higher target chance of detection under those same assumptions. These are design targets, not guarantees for an individual study. When the effect to be detected is smaller, the required number of participants or events is larger, because smaller differences are harder to distinguish from random variation.

These calculations are planning illustrations based on the observed effect, not observed power. They do not indicate the probability that the trial’s result is true or the probability that a future study will succeed. The numbers are sensitive to the effect size and assumptions used, and the registry record does not establish that these planning calculations were used to design this trial.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

d is the total number of events needed (Schoenfeld's formula) with 1:1 allocation and proportional hazards.

Worked calculation for this trial

1. Hazard ratio HR = 0.550, so ln(HR) = -0.5978.
2. d = 4 × (1.96 + 0.842)² / [ln(0.550)]² = 87.8, rounded up to 88 events in total for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
hr <- 0.55                              # observed hazard ratio
events_needed <- function(power, frac = 1) ceiling(round(4 * (z_a + qnorm(power))^2 / log(hr^frac)^2, 6))   # Schoenfeld, 1:1 allocation
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: events = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(events_needed(0.80, f), big.mark = ","), format(events_needed(0.90, f), big.mark = ",")))

# Simulation: given d total events under proportional hazards, events in the treatment arm are Binomial(d, hr / (1 + hr)).
# The score (log-rank type) statistic is (D1 - d / 2) / sqrt(d / 4).
set.seed(1039376)
d    <- events_needed(0.80)
reps <- 20000
D1 <- rbinom(reps, d, hr / (1 + hr))
z  <- (D1 - d / 2) / sqrt(d / 4)
cat(sprintf("Simulated power with %s events: %.3f (%d replicates)\n", format(d, big.mark = ","), mean(abs(z) > z_a), reps))

Output from running the code

100% of observed effect: events = 88 (80% power), 118 (90% power)
 75% of observed effect: events = 157 (80% power), 210 (90% power)
 50% of observed effect: events = 352 (80% power), 471 (90% power)
Simulated power with 88 events: 0.775 (20000 replicates)

The simulation uses the fact that, with d events in total and proportional hazards, the number of events in the treatment arm is binomial. It is an approximation that conditions on the total number of events, and it should land close to the target power.

14. Group-Sequential Design Analysis

Many time-to-event trials, especially in oncology, stop or report early when interim data are overwhelming, so a single fixed-sample number understates the real design problem. The calculation below is an illustrative group-sequential design built from this trial's posted control median and hazard ratio. The registry record does not state the planned number of looks or the spending function, so the design is a planning illustration, not a reconstruction of the protocol. Assumed: one-sided α = 0.025, 90% power, three equally spaced looks on information, Lan-DeMets O'Brien-Fleming spending, 24 months of accrual, 60 months in total and a 1% monthly dropout hazard.

Under these assumptions the design needs about 186 participants in total, with the boundaries below.

Fixed design versus group-sequential alternatives

Group-sequential designs cost a small increase in maximum sample size and events compared with the fixed design, in exchange for the chance to stop early for overwhelming efficacy. O'Brien-Fleming spending keeps early boundaries very conservative and the final boundary close to the fixed-design value, whereas Pocock spending spends more alpha early.

Sensitivity to a smaller true effect

Planning for exactly the observed effect is optimistic, because observed effects in published trials tend to be somewhat larger than the true effect. The table repeats the main design (three looks, O'Brien-Fleming spending, 90% power) for smaller true hazard ratios.

For context, this trial enrolled 480 participants.

Cross-check, upper boundaries: gsDesign 3.71, 2.511, 1.993 | rpact 3.71, 2.511, 1.993. Agreement between the two packages confirms the boundary calculation.

R code and output

suppressWarnings(suppressMessages({ library(gsDesign); library(rpact) }))
med_control <- 16.89          # control-arm median, months (converted from the posted unit)
hr          <- 0.55          # hazard ratio used for planning
lambdaC     <- log(2) / med_control
eta         <- 0.01               # dropout hazard per month (assumption)
acc_months  <- 24                 # accrual duration (assumption)
study_months<- 60                 # total study duration (assumption)

design <- function(k, sfu, beta, h = hr) gsSurv(k = k, test.type = 1, alpha = 0.025, beta = beta, sfu = sfu,
  lambdaC = lambdaC, hr = h, hr0 = 1, eta = eta, gamma = 1, R = acc_months, T = study_months, minfup = study_months - acc_months)

# Main design: 3 looks, Lan-DeMets O'Brien-Fleming spending, one-sided alpha 0.025, 90% power
x <- design(3, sfLDOF, 0.10)
cat(sprintf("N_TOTAL|%s\n", format(ceiling(sum(x$gamma * x$R)), big.mark = ",")))
for (i in 1:3) cat(sprintf("GS|%d|%.1f|%.0f|%.3f|%.5f|%.5f\n", i, x$T[i], x$n.I[i], x$upper$bound[i], pnorm(-x$upper$bound[i]), cumsum(x$upper$spend)[i]))
cat("\n"); print(gsBoundSummary(x))

# Comparison of designs
cmp <- list(list("Fixed design, one analysis", 1, sfLDOF), list("Two looks, O'Brien-Fleming", 2, sfLDOF),
            list("Three looks, O'Brien-Fleming", 3, sfLDOF), list("Three looks, Pocock", 3, sfLDPocock))
cat("\n")
for (b in c(0.20, 0.10)) for (d in cmp) {
  y <- design(d[[2]], d[[3]], b)
  cat(sprintf("DES|%s|%d|%.0f|%s|%.1f\n", d[[1]], round(100 * (1 - b)), tail(y$n.I, 1), format(ceiling(sum(y$gamma * y$R)), big.mark = ","), tail(y$T, 1)))
}

# Sensitivity: what if the true effect is smaller than the observed one? (3 looks, O'Brien-Fleming, 90% power)
cat("\n")
for (fr in c(1, 0.75, 0.5)) {
  y <- design(3, sfLDOF, 0.10, exp(log(hr) * fr))
  cat(sprintf("SENS|%.2f|%.3f|%.0f|%s\n", fr, exp(log(hr) * fr), tail(y$n.I, 1), format(ceiling(sum(y$gamma * y$R)), big.mark = ",")))
}

# Independent cross-check of the boundaries with rpact
r <- getDesignGroupSequential(kMax = 3, alpha = 0.025, beta = 0.10, sided = 1, typeOfDesign = "asOF", informationRates = x$timing)
cat(sprintf("\nCross-check, upper boundaries: gsDesign %s | rpact %s\n", paste(round(x$upper$bound, 3), collapse = ", "), paste(round(r$criticalValues, 3), collapse = ", ")))

Method: LachinFoulkes 
    Analysis               Value Efficacy
   IA 1: 33%                   Z   3.7103
      N: 160         p (1-sided)   0.0001
  Events: 40        ~HR at bound   0.3065
   Month: 21    P(Cross) if HR=1   0.0001
             P(Cross) if HR=0.55   0.0338
   IA 2: 67%                   Z   2.5114
      N: 186         p (1-sided)   0.0060
  Events: 79        ~HR at bound   0.5678
   Month: 33    P(Cross) if HR=1   0.0060
             P(Cross) if HR=0.55   0.5603
       Final                   Z   1.9930
      N: 186         p (1-sided)   0.0231
 Events: 119        ~HR at bound   0.6930
   Month: 60    P(Cross) if HR=1   0.0250
             P(Cross) if HR=0.55   0.9000



Cross-check, upper boundaries: gsDesign 3.71, 2.511, 1.993 | rpact 3.71, 2.511, 1.993

15. Analyses Reported by the Sponsor

For progression-free survival, the registry reports a sponsor analysis using a stratified log-rank test and a hazard ratio of 0.55, with a 95% confidence interval from 0.43 to 0.70 and p < 0.001. The posted comparative estimate and the sponsor-reported analysis agree. The record does not indicate a discrepancy for this primary result.

The distinction between a sponsor-reported analysis and a simple re-calculation is important. Recalculations from posted summary statistics are unadjusted checks and may not reproduce methods that use participant-level information, stratification, censoring, or other features of the analysis. For time-to-event outcomes, interpretation should therefore rely on the sponsor’s reported hazard ratio and test rather than replacing them with a calculation from arm-level medians.

Some secondary time-to-event outcomes also have sponsor-reported hazard ratios and stratified log-rank p-values. The response-improvement outcome has posted arm counts but no sponsor-reported comparative analysis in the registry record; a simple comparison based on those counts should be understood as an unadjusted recalculation, not as the sponsor’s analysis. The registry does not report a sponsor analysis for every posted secondary outcome in the same form.

Agreement between the posted primary result and the sponsor’s own analysis is useful for identifying which estimate represents the reported trial analysis. It does not address limitations such as the open-label design, investigator assessment, unreported missing-data procedures, or unreported multiplicity strategy. Those questions require details not reported in the registry record.

16. Multiplicity, Missing Data and Analysis Populations

The registry lists 27 outcome measures and 25 posted secondary outcomes, in addition to the primary endpoint. Testing multiple outcomes increases the chance that at least one result appears notable by chance, even when there is no true effect for that outcome. Statistical approaches can control this issue through adjustments, prespecified hierarchies, or other strategies. Whether any such approach was used for this trial is not reported in the registry record. The relationship among the secondary hypotheses and any planned testing sequence is also not reported.

The primary analysis population is defined as intent-to-treat: all participants randomized. This is an important description of the target group for the primary result, but it does not by itself explain how missing endpoint observations were handled. The registry record does not report the missing-data procedures, censoring details, or sensitivity analyses for missing outcomes. It also does not provide enough information to determine whether all secondary outcomes used the same analysis population.

Other elements of the statistical plan are not reported in the registry record, including the original sample-size justification, interim-analysis procedures, and the detailed stratification factors for the reported log-rank tests. The registry’s status is terminated, but the reason for termination is not reported. No inference about the reason, its relation to the results, or the timing of any decision can be made from the recorded status alone.

These omissions matter because they limit evaluation of whether the posted analyses fully match the original plan and how robust results are to alternative assumptions. They do not invalidate the reported statistics, but they make it harder to assess selective reporting, multiplicity, or sensitivity to missing information. The primary outcome should be interpreted using the sponsor-reported analysis while recognizing that these aspects of the analysis plan are not available in the registry record.

17. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: pneumonia (15.5%), pyrexia (7.9%), febrile neutropenia (7.5%), sepsis (3.3%), anaemia (2.9%).

The registry reports serious adverse events affecting 120 participants in the ofatumumab group and 120 in the observation group. The corresponding groups at risk are listed as 239 and 241. These are counts, not estimates of causal risk attributable to treatment. The registry also lists deaths as 88 in the ofatumumab group and 87 in the observation group. The record does not provide enough information in these figures alone to determine the causes of death or their relationship to study treatment.

The most frequently listed serious adverse event terms include pneumonia at 15.5%, pyrexia at 7.9%, febrile neutropenia at 7.5%, sepsis at 3.3%, anaemia at 2.9%, and neutropenia at 2.1%. These are registry-reported percentages; the precise basis for each percentage should be interpreted according to the registry’s adverse-event definitions and reporting conventions.

Serious adverse event counts should be read alongside the denominators and the way events were collected. A count does not show how long participants were at risk, how many events a participant could have experienced, or whether an event was judged related to treatment. The available record does not provide all those details in the posted figures. Because the trial was open-label and the comparison includes observation, these safety data describe reported events during the study; they do not by themselves establish that ofatumumab caused or prevented any particular event.

18. What the Result Does, and Does Not, Mean

The primary result shows a statistically clear difference in investigator-assessed progression-free survival under the sponsor-reported analysis. The hazard ratio is below 1, its 95% confidence interval is below 1, and the reported p-value is p < 0.001. The arm-specific median estimates also describe longer estimated progression-free survival for the ofatumumab arm than the observation arm in the posted results. These findings answer the registry’s primary comparative question for the stated endpoint and analysis population.

The result does not by itself establish how much an individual participant will benefit, whether the difference is clinically important to every participant, or whether the same estimate would apply to other populations or treatment settings. A hazard ratio is a relative time-to-event measure, not an absolute probability of benefit at a particular time. The medians describe the estimated distributions and do not predict an individual’s course.

The primary result also does not prove an overall-survival difference. The overall-survival confidence interval includes 1, and the reported p-value is 0.605. Nor does a non-conclusive comparison prove that the arms are equivalent. The secondary outcomes address distinct questions, and their interpretation is limited by the lack of a reported multiplicity strategy and by the varying level of analysis detail in the registry record.

The data do not establish a complete benefit-risk balance. Serious adverse event counts, event terms, and deaths provide safety context, but they do not alone determine causality or describe all relevant harms. The trial was open-label, progression was investigator-assessed, and details of missing-data handling and the reason for termination are not reported in the registry record. These limitations should accompany any interpretation of what the trial found.

In short, the registry’s principal statistical finding is an association between assignment to ofatumumab maintenance and a lower estimated hazard of progression or death compared with observation in the analyzed population. The strength of that statement is tied to the trial’s design, endpoint assessment, and reported analysis; it should not be expanded into claims that the registry data do not establish.

19. Why This Trial Matters Statistically

This trial illustrates why endpoint choice matters in clinical research. Progression-free survival combines progression and death and captures when either event occurs, while overall survival asks a different question about time to death. The posted results demonstrate that these outcomes need not give equally precise or statistically conclusive comparisons. A strong result for one endpoint should not be automatically transferred to another.

It also provides a useful example of the difference between a median and a hazard ratio. The medians summarize each arm’s estimated time-to-event distribution at its midpoint; the hazard ratio compares event hazards over follow-up. They are related descriptions of the data but are not interchangeable effect measures. Reading both alongside their uncertainty intervals gives a more complete statistical interpretation than focusing on a single number.

The registry’s open-label design and investigator-assessed primary outcome highlight the value of considering how an endpoint was measured, not only how it was analyzed. The stratified log-rank test and sponsor-reported hazard ratio state the comparison used, while unreported details such as stratification factors and missing-data handling limit independent assessment of the analysis.

Finally, the secondary outcomes and safety figures show why a trial’s evidence must be considered as a whole. Multiple outcomes create multiplicity concerns, and safety counts require context about denominators, exposure, and attribution. The registry record documents a primary progression-free survival result, but it does not report all details needed to settle every question about robustness, broader outcomes, or the reason for termination. That combination makes the study a practical example of separating a clear statistical finding from the wider claims the data can support.

20. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several limitations specific to this trial affect interpretation. First, the study was open-label. Participants and investigators knew the assigned arm, and the primary endpoint was assessed by investigators. The registry does not report masked central review of progression, so the possibility that knowledge of assignment influenced assessment cannot be evaluated from the record.

Second, the primary endpoint depends on progression criteria applied by investigators. The registry describes IWCLL-based criteria, including multiple clinical and laboratory indicators, but does not provide detail about consistency of assessment across centers or how disagreements were resolved. The registry also does not report the stratification factors used in the primary log-rank analysis.

Third, the trial status is terminated and the reason is not reported in the registry record. The record does not provide the original sample-size justification, interim-analysis plan, detailed statistical analysis plan, or missing-data procedures. This restricts assessment of whether the posted analyses followed the original plan and how sensitive they might be to missing observations or alternative assumptions.

Fourth, the registry lists many secondary outcomes, but a multiplicity strategy is not reported. Some secondary comparisons have sponsor-reported analyses while others are reported as counts or outcome descriptions without the same inferential detail. This uneven reporting and the number of outcomes limit the weight that should be placed on individual secondary findings.

Finally, the adverse-event figures are not a complete causal safety assessment. Counts and listed event percentages do not, by themselves, establish attribution, exposure-adjusted rates, or the timing of events. The posted registry information is therefore informative about reported outcomes but leaves important design, analysis, and safety details unresolved.

21. Related Tutorials

22. Related Statistical Calculators

23. Sources

• ClinicalTrials.gov: Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy — NCT01039376.
• Registry record last updated 2019-07-30; status last verified 2019-07.
• Results first posted 2015-04-21.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

24. Record Summary

The registry describes a randomized, Phase III, open-label, multicenter study comparing ofatumumab maintenance with observation in relapsed chronic lymphocytic leukemia after response to induction therapy. The primary endpoint was investigator-assessed progression-free survival from randomization until progression or death, analyzed in the intent-to-treat population using a stratified log-rank test.

The sponsor-reported primary hazard ratio was 0.55, with a 95% confidence interval from 0.43 to 0.70 and p < 0.001. The registry reports longer median progression-free survival in the ofatumumab arm than in the observation arm. Secondary outcomes and safety results provide additional context, but multiplicity handling, missing-data procedures, and the reason for termination are not reported in the registry record.